BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28134921)

  • 1. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era.
    Hegerova L; Cao Q; Lazaryan A; McClune BL; Weisdorf DJ; Brunstein CG; Bachanova V
    Bone Marrow Transplant; 2017 May; 52(5):697-703. PubMed ID: 28134921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
    Anderlini P; Saliba RM; Ledesma C; Plair T; Alousi AM; Hosing CM; Khouri IF; Nieto Y; Popat UR; Shpall EJ; Fanale MA; Hagemeister FB; Oki Y; Neelapu S; Romaguera JE; Younes A; Champlin RE
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1333-1337. PubMed ID: 27064056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
    Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
    Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
    Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
    Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R; Palmer JM; Martin P; Tsai N; Kim Y; Chen BT; Popplewell L; Siddiqi T; Thomas SH; Mott M; Sahebi F; Armenian S; Leonard J; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2136-2140. PubMed ID: 26211987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.
    Chen R; Palmer JM; Tsai NC; Thomas SH; Siddiqi T; Popplewell L; Farol L; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1864-8. PubMed ID: 25008328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
    Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
    Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of brentuximab vedotin as salvage therapy pre-allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho-proliferative disorders: a single centre experience.
    Mediwake H; Morris K; Curley C; Butler J; Kennedy G
    Intern Med J; 2017 May; 47(5):574-578. PubMed ID: 28247950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
    Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
    Chen R; Palmer JM; Thomas SH; Tsai NC; Farol L; Nademanee A; Forman SJ; Gopal AK
    Blood; 2012 Jun; 119(26):6379-81. PubMed ID: 22611160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.
    Bonthapally V; Yang H; Ayyagari R; Tan RD; Cai S; Wu E; Gautam A; Chi A; Huebner D
    Curr Med Res Opin; 2015; 31(7):1377-89. PubMed ID: 25950500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of transplantation in Hodgkin lymphoma.
    Broccoli A; Zinzani PL
    Br J Haematol; 2019 Jan; 184(1):93-104. PubMed ID: 30407612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Allogeneic hematopoietic stem cell transplantation following treatment with brentuximab vedotin for refractory Hodgkin lymphoma].
    Yamane Y; Koda Y; Kohashi S; Kato J; Hashida R; Sakurai M; Toyama T; Kikuchi T; Okayama M; Kasahara H; Karigane D; Shimizu T; Okamoto S; Mori T
    Rinsho Ketsueki; 2017; 58(7):755-759. PubMed ID: 28781270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party.
    Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Blaise D; Peggs KS; Afanasyev B; Diez-Martin JL; Corradini P; Michonneau D; Robinson S; Gutiérrez García G; Bonifazi F; Yakoub-Agha I; Gülbas Z; Bloor A; Delage J; Esquirol A; Malladi R; Scheid C; El-Cheikh J; Ghesquières H; Montoto S; Dreger P; Sureda A
    Cancer; 2019 Jan; 125(1):90-98. PubMed ID: 30351488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
    Gaudio F; Mazza P; Carella AM; Mele A; Palazzo G; Pisapia G; Carluccio P; Pastore D; Cascavilla N; Specchia G; Pavone V
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):35-40. PubMed ID: 30293754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM).
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):15-7. PubMed ID: 24870877
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
    Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
    Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
    [No Abstract]   [Full Text] [Related]  

  • 19. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Devetten MP; Hari PN; Carreras J; Logan BR; van Besien K; Bredeson CN; Freytes CO; Gale RP; Gibson J; Giralt SA; Goldstein SC; Gupta V; Marks DI; Maziarz RT; Vose JM; Lazarus HM; Anderlini P
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):109-17. PubMed ID: 19135949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival.
    Spina F; Radice T; De Philippis C; Soldarini M; Di Chio MC; Dodero A; Guidetti A; Viviani S; Corradini P
    Leuk Lymphoma; 2019 Jan; 60(1):101-109. PubMed ID: 29716416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.